منابع مشابه
Infective Agents and Multiple Sclerosis.
Although the pathogenesis of multiple sclerosis remains obscure, much pathological and clinical evidence suggests an infective agent as a possible aetiological factor. If such an agent is responsible for initiating the disease it seems probable that there is a latent period of several years before the development of clinical features of multiple sclerosis. By that time it might be impossible to...
متن کاملMultiple Sclerosis: Overview of Disease-Modifying Agents
Multiple sclerosis (MS) is a chronic autoimmune disease that usually affects young adults, causing progressive physical and cognitive disability. Since the 1990s, its treatment has been based on parenteral medications known collectively as immunomodulators. This drug class is considered safe and usually prevents 30% of MS relapses. Drugs in this class exert almost the same efficacy and require ...
متن کاملDisease Modifying Agents for Multiple Sclerosis
OBJECTIVE To summarize major clinical trials which evaluate the efficacy and safety data of approved disease modifying agents for the treatment of various types of multiple sclerosis. DATA SOURCES A MEDLINE (1966 to August 2008) search of clinical trials using the terms multiple sclerosis, interferon, glatiramer, mitoxantrone and natalizumab was performed. A manual bibliographic search was al...
متن کاملSystematic review: Superparamagnetic Iron Oxide nanoparticles as contrast agents in diagnosis of multiple sclerosis
Several MRI contrast agents (CAs) are used in medical diagnosis that gadolinium (Gd3+) is the most widely used as contrast agents. Unfortunately, its toxicity is due to its inefficiency. In this review, we discuss about the ability of SPIONs in MRI and application in Multiple Sclerosis diagnosis. Superparamagnetic iron oxide nanoparticles (SPIONs) such as magnetite nanoparticles are used as goo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1965
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.1.5429.226